Chardan Capital Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)


In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Intellia Therapeutics (NTLA), with a price target of $57.50. The company’s shares opened today at $19.

Livshits wrote:

“We believe Intellia is making steady progress towards the clinic in collaboration with industry and academic partners, with a focus on platform modularity and being best rather than first. We look forward to more data in 2019, particularly on the ex vivo front, where details on the WT1-targeted T cell receptor asset design have been comparatively limited to date. After a pre-IND meeting with the FDA, focus in ATTR shifts to clinic readiness (i.e. tox, manufacturing, trial design). Executing on earlier guidance, Intellia announced it has begun IND-enabling toxicology studies for NTLA-2001. Recall, the asset is being developed in collaboration Regeneron Pharmaceuticals (unrated), with Intellia as the lead in development and commercialization.”

According to TipRanks.com, Livshits is a 4-star analyst with an average return of 22.7% and a 75.0% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Logicbio Therapeutics Inc, and Crispr Therapeutics AG.

Intellia Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $29.38.

See today’s analyst top recommended stocks >>

The company has a one-year high of $32.95 and a one-year low of $11.03. Currently, Intellia Therapeutics has an average volume of 605.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts